Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy [published correction appears in Ann Intern Med. 2006 Mar 21;144(6):460]. Ann Intern Med. 2006;144(2):127-134. doi:10.7326/0003-4819-144-2-200601170-00010
Andrilla CHA, Jones KC, Patterson DG. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine. J Rural Health. 2020;36(2):187-195. doi:10.1111/jrh.12404
Bharat C, Webb P, Wilkinson Z, et al. Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis. Addiction. 2023;118(9):1624-1648. doi:10.1111/add.16200
Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373:n784. Published 2021 May 19. doi:10.1136/bmj.n784
Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry. 2021;26(1):41-50. doi:10.1038/s41380-020-00949-3
Cousins SJ, Radfar SR, Crèvecoeur-MacPhail D, Ang A, Darfler K, Rawson RA. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County. J Subst Abuse Treat. 2016;63:66-71. doi:10.1016/j.jsat.2015.12.004
D'Onofrio G, Herring AA, Perrone J, et al. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024;7(7):e2420702. Published 2024 Jul 1. doi:10.1001/jamanetworkopen.2024.20702
D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644. doi:10.1001/jama.2015.3474
Edinoff AN, Flanagan CJ, Roberts LT, et al. Cebranopadol for the Treatment of Chronic Pain. Curr Pain Headache Rep. 2023;27(10):615-622. doi:10.1007/s11916-023-01148-9
Gleason-Comstock, J., Calhoun, C.B., Locke, B.J. et al. People who use drugs engagement in substance use disorder services and harm reduction: evaluation, challenges and future direction of a community-based intervention. Subst Abuse Treat Prev Policy 19, 24 (2024). https://doi.org/10.1186/s13011-024-00601-1
Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014. JAMA Pediatr. 2017;171(8):747-755. doi:10.1001/jamapediatrics.2017.0745
Harder VS, Villanti AC, Heil SH, et al. Opioid use disorder treatment in rural settings: The primary care perspective. Prev Med. 2021;152(Pt 2):106765. doi:10.1016/j.ypmed.2021.106765
Herring AA, Vosooghi AA, Luftig J, et al. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Netw Open. 2021;4(7):e2117128. Published 2021 Jul 1. doi:10.1001/jamanetworkopen.2021.17128
Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs. JAMA Psychiatry. 2022;79(9):932-934. doi:10.1001/jamapsychiatry.2022.1776
Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107 Suppl 1(0 1):5-27. doi:10.1111/j.1360-0443.2012.04035.x
Martin M, Krawczyk N. Linking Hospitalized Patients With Opioid Use Disorder to Treatment-The Importance of Care Transitions. JAMA Netw Open. 2024;7(2):e2356382. Published 2024 Feb 5. doi:10.1001/jamanetworkopen.2023.56382
McEachern J, Adye-White L, Priest KC, et al. Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy. Int J Drug Policy. 2019;64:30-33. doi:10.1016/j.drugpo.2018.08.006
McDonell MG, Graves MC, West II, et al. Utility of Point-of-care Urine Drug Tests in the Treatment of Primary Care Patients With Drug Use Disorders. J Addict Med. 2016;10(3):196-201. doi:10.1097/ADM.0000000000000220
McLellan, A T et al. "Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation." JAMA vol. 284,13 (2000): 1689-95. doi:10.1001/jama.284.13.1689
NIDA. 2024, June 28. Most Americans don't know that primary care physicians can prescribe addiction treatment. Retrieved from https://nida.nih.gov/news-events/news-releases/2024/06/most-americans-dont-know-that-primary-care-physicians-can-prescribe-addiction-treatment on 2025, April 11
O'Connor, Patrick G. "Methods of detoxification and their role in treating patients with opioid dependence." JAMA vol. 294,8 (2005): 961-3. doi:10.1001/jama.294.8.961
Owens, M.D., Chen, J.A., Simpson, T.L. et al. Barriers to addiction treatment among formerly incarcerated adults with substance use disorders. Addict Sci Clin Pract 13, 19 (2018). https://doi.org/10.1186/s13722-018-0120-6
Peterkin, Alyssa et al. "Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder." The Medical clinics of North America vol. 106,1 (2022): 61-80. doi:10.1016/j.mcna.2021.08.009
Randhawa PA, Brar R, Nolan S. Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market. CMAJ. 2020;192(3):E73. doi:10.1503/cmaj.74018
Serdarevic M, Cvitanovich M, MacDonald BR, d'Etienne J, DeMoss D, Ojha RP. Emergency Department Bridge Model and Health Services Use Among Patients With Opioid Use Disorder. Ann Emerg Med. 2023;82(6):694-704. doi:10.1016/j.annemergmed.2023.06.014
Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. Drug Alcohol Rev. 2022;41(2):444-448. doi:10.1111/dar.13394
Snyder H, Chau B, Kalmin MM, et al. High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids. JAMA Netw Open. 2023;6(3):e231572. Published 2023 Mar 1. doi:10.1001/jamanetworkopen.2023.1572
Spreen LA, Dittmar EN, Quirk KC, Smith MA. Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review. Pharmacotherapy. 2022;42(5):411-427. doi:10.1002/phar.2676
Stimmel, B et al. "Ability to remain abstinent after methadone detoxification. A six-year study." JAMA vol. 237,12 (1977): 1216-20.
Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. N Engl J Med. 2022;387(22):2033-2044. doi:10.1056/NEJMoa2203318
Thakrar AP, Christine PJ, Siaw-Asamoah A, et al. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. JAMA Netw Open. 2024;7(9):e2435895. Published 2024 Sep 3. doi:10.1001/jamanetworkopen.2024.35895
Varshneya NB, Thakrar AP, Lambert E, Huhn AS. Opioid Use Disorder Treatment in the Fentanyl Era. J Addict Med. 2023;17(1):118-119. doi:10.1097/ADM.0000000000001013
Wason, K.F.; Potter, A.L.; Alves, J.D.; Loukas, V.L.; Lastimoso, C.S.; Sodder, S.B.; Caputo, A.M.; and LaBelle, C.T. Massachusetts Nurse Care Manager Model of Office Based Addiction Treatment: Clinical Guidelines. Unpublished treatment manual, Boston Medical Center, May 2021.
Wong S, Fabiano N, Webber D, Kleinman RA. High-Dose Buprenorphine Initiation: A Scoping Review. J Addict Med. 2024;18(4):349-359. doi:10.1097/ADM.0000000000001296
